Expand beyond the one biomarker, one drug paradigm with expert molecular profiling and drug-response analyses using QIAGEN Real-World Insights (RWI)
Biomarkers in a patient’s tumor are becoming increasingly critical in determining the appropriate treatment. As more patients undergo diagnostic sequencing, vast amounts of genomic data are being collected, enabling a paradigm shift in how drugs are developed and trials designed.
QIAGEN RWI provides real-world molecular profiling and cancer diagnosis data from over 200,000 individual cancer cases to help you better understand the genomic characteristics of your target population.
At QIAGEN, we have one of the largest real-world genomic profiling datasets in the country, offering genomic data from over 200,000 cancer cases expertly classified by Ph.D. scientists and oncologists. Using this information, you can develop more efficient and effective trials for the populations most likely to respond to your targeted therapeutics.
QIAGEN RWI helps you:
QIAGEN’s RWI portfolio combines robust real-world genomic data from over 200,000 cancer cases and advanced analytics to achieve better decisions faster in early drug and test development.
To access RWI, you can:
Do you have novel questions, hypotheses, and hurdles to overcome? Our team of scientists, bioinformaticists, and clinicians can help you strategize, plan a project, and deliver within your timeline.
Choose the best biomarkers and cancer indications for your molecularly targeted therapies
Identify appropriate patient cohorts and enhance your CDx design to improve stratification and success
More easily find the right patients and quickly move to recruitment and regulatory acceptance